Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Completed 6Terminated 5Unknown 4Withdrawn 2Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Neoplasms 83Carcinoma, Non-Small-Cell Lung 79Breast Neoplasms 71Leukemia, Myeloid, Acute 39Colorectal Neoplasms 37Recurrence 36Prostatic Neoplasms 34Neoplasm Metastasis 30Multiple Myeloma 28Lymphoma 26Pancreatic Neoplasms 25Melanoma 25Lymphoma, Non-Hodgkin 24Lung Neoplasms 24Leukemia, Lymphocytic, Chronic, B-Cell 23Ovarian Neoplasms 22Lymphoma, Follicular 22Carcinoma, Hepatocellular 22Carcinoma, Renal Cell 21Stomach Neoplasms 19Squamous Cell Carcinoma of Head and Neck 19Lymphoma, Large B-Cell, Diffuse 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Myelodysplastic Syndromes 18Leukemia 18Head and Neck Neoplasms 18Urinary Bladder Neoplasms 17Hematologic Neoplasms 14Carcinoma 13Uterine Cervical Neoplasms 12

Interventions

Norepinephrine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × INDUSTRY × Radiodermatitis × Clear all
NCT04692389 2022-02-08

JalosomeĀ® Soothing Gel Efficacy Grade 2 or 3 Radiodermatitis.

Welcare Industries SpA

Phase NA Withdrawn

Neoplasms, Pain, Radiodermatitis

NCT01544504 2012-05-28

Exploratory Study of Topical Norepinephrine in Breast Cancer Patients Receiving Radiotherapy

ProCertus BioPharm, Inc

Phase 1/2 Withdrawn

Radiodermatitis

Data powered by HemOnc (CC BY 4.0) Colophon ⚔